Marc Wirden

3.4k total citations
105 papers, 2.1k citations indexed

About

Marc Wirden is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Marc Wirden has authored 105 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 99 papers in Infectious Diseases, 95 papers in Virology and 20 papers in Epidemiology. Recurrent topics in Marc Wirden's work include HIV Research and Treatment (95 papers), HIV/AIDS drug development and treatment (95 papers) and HIV/AIDS Research and Interventions (56 papers). Marc Wirden is often cited by papers focused on HIV Research and Treatment (95 papers), HIV/AIDS drug development and treatment (95 papers) and HIV/AIDS Research and Interventions (56 papers). Marc Wirden collaborates with scholars based in France, United States and Italy. Marc Wirden's co-authors include Vincent Cálvez, Anne‐Geneviève Marcelin, Christine Katlama, Anne Simon, Gilles Peytavin, Isabelle Malet, Cathia Soulié, Marc‐Antoine Valantin, Constance Delaugerre and Dominique Costagliola and has published in prestigious journals such as PLoS ONE, Clinical Infectious Diseases and Kidney International.

In The Last Decade

Marc Wirden

100 papers receiving 2.0k citations

Peers

Countries citing papers authored by Marc Wirden

Since Specialization

Citations

This map shows the geographic impact of Marc Wirden's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marc Wirden with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marc Wirden more than expected).

Fields of papers citing papers by Marc Wirden

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marc Wirden. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marc Wirden. The network helps show where Marc Wirden may publish in the future.

Co-authorship network of co-authors of Marc Wirden

This figure shows the co-authorship network connecting the top 25 collaborators of Marc Wirden. A scholar is included among the top collaborators of Marc Wirden based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marc Wirden. Marc Wirden is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Uptake of drug-reduced antiretroviral strategies and impact on costs over 2015–22: experience from an HIV clinic in Paris, France 2025 ·Journal of Antimicrobial Chemotherapy ·Luis Sagaon‐Teyssier, (unknown), M.A. Valantin, (unknown), Roland Tubiana, Sophie Seang, (unknown), (unknown), (unknown), Marc Wirden, Cathia Soulié, Gilles Peytavin, (unknown), (unknown), Romain Palich, (unknown)	0
2	Neutralization Heterogeneity of UK and South African Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants in BNT162b2-Vaccinated or Convalescent Coronavirus Disease 2019 (COVID-19) Healthcare Workers 2021 ·Clinical Infectious Diseases ·Stéphane Marot, Isabelle Malet, Valentin Leducq, Basma Abdi, Elisa Teyssou, Cathia Soulié, Marc Wirden, Christophe Rodriguez, Slim Fourati, Jean–Michel Pawlotsky, David Boutolleau, Sonia Burrel, Vincent Cálvez, Anne‐Geneviève Marcelin, Aude Jary	9
3	Intermittent two-drug antiretroviral therapies maintain long-term viral suppression in real life in highly experienced HIV-infected patients 2021 ·Journal of Antimicrobial Chemotherapy ·Romain Palich, Basma Abdi, Marc Wirden, Panagiota Lourida, Roland Tubiana, (unknown), Marc‐Antoine Valantin, Luminita Schneider, Sophie Seang, Rachid Agher, Anne Simon, Cathia Soulié, Minh Lê, Gilles Peytavin, Vincent Cálvez, Anne‐Geneviève Marcelin, Christine Katlama	1
4	Kinetics of Archived M184V Mutation in Treatment-Experienced Virally Suppressed HIV-Infected Patients 2021 ·The Journal of Infectious Diseases ·Romain Palich, Elisa Teyssou, Sophie Sayon, Basma Abdi, Cathia Soulié, Lise Cuzin, Roland Tubiana, Marc‐Antoine Valantin, Luminita Schneider, Sophie Seang, Marc Wirden, Valérie Pourcher, Christine Katlama, Vincent Cálvez, Anne‐Geneviève Marcelin	12
5	Multicenter comparison of the Cobas 6800 system with the RealStar RT-PCR kit for the detection of SARS-CoV-2 2020 ·Journal of Clinical Virology ·Marc Wirden, Linda Feghoul, Mélanie Bertine, (unknown), Quentin Le Hingrat, Basma Abdi, David Boutolleau, Valentine Marie Ferré, Aude Jary, Constance Delaugerre, Anne‐Geneviève Marcelin, Diane Descamps, Jérôme LeGoff, Benoît Visseaux, Marie‐Laure Chaix	17
6	INSTI-Based Triple Regimens in Treatment-Naïve HIV-Infected Patients Are Associated With HIV-RNA Viral Load Suppression at Ultralow Levels 2019 ·Open Forum Infectious Diseases ·Sidonie Lambert-Niclot, Anders Boyd, Djeneba Fofana, Nadia Valin, Marc Wirden, Jean‐Luc Meynard, Romain Palich, Rachid Agher, Marc‐Antoine Valantin, Vincent Cálvez, Christine Katlama, Pierre‐Marie Girard, Anne‐Geneviève Marcelin, Laurence Morand‐Joubert	7
7	Caution is needed in interpreting HIV transmission chains by ultradeep sequencing 2018 ·AIDS ·Ève Todesco, Marc Wirden, Ruxandra Câlin, Anne Simon, Sophie Sayon, Francis Barin, Christine Katlama, Vincent Cálvez, Anne‐Geneviève Marcelin, Stéphane Hué	9
8	Genetic barrier to the development of resistance to rilpivirine and etravirine between HIV-1 subtypes CRF02_AG and B 2013 ·Journal of Antimicrobial Chemotherapy ·Djeneba Fofana, Cathia Soulié, Almoustapha Issiaka Maïga, Slim Fourati, Isabelle Malet, Marc Wirden, A. Tounkara, (unknown), Vincent Cálvez, Anne‐Geneviève Marcelin, Sidonie Lambert-Niclot	6
9	Highly multidrug-resistant HIV: clonal analysis and therapeutic strategies 2013 ·Journal of Antimicrobial Chemotherapy ·Ève Todesco, Sophie Sayon, S. Fourati, Roland Tubiana, Anne Simon, Nadine Ktorza, Lars Schneider, Gilles Peytavin, Isabelle Malet, Peter Van den Eede, Christine Katlama, Vincent Cálvez, Anne‐Geneviève Marcelin, Marc Wirden	3
10	Efficacy of raltegravir switching strategies in HIV-infected patients with suppressed viraemia according to the genotypic sensitivity score 2013 ·Infection ·Fabienne Caby, (unknown), Catherine Blanc, Cathia Soulié, (unknown), Gilles Peytavin, Rachid Agher, (unknown), Roland Tubiana, Marc Wirden, Vincent Cálvez, Anne‐Geneviève Marcelin, Christine Katlama	1
11	Historical HIV-RNA resistance test results are more informative than proviral DNA genotyping in cases of suppressed or residual viraemia 2011 ·Journal of Antimicrobial Chemotherapy ·Marc Wirden, Cathia Soulié, Marc‐Antoine Valantin, S. Fourati, Anne Simon, Sidonie Lambert-Niclot, Manuela Bonmarchand, (unknown), Anne‐Geneviève Marcelin, Christine Katlama, Vincent Cálvez	65
12	International Cohort Analysis of the Antiviral Activities of Zidovudine and Tenofovir in the Presence of the K65R Mutation in Reverse Transcriptase 2010 ·Antimicrobial Agents and Chemotherapy ·Philip Grant, Jonathan Taylor, Andrew Nevins, Vincent Cálvez, Anne‐Geneviève Marcelin, Marc Wirden, Andrew Zolopa	9
13	Raltegravir has no residual antiviral activity in vivo against HIV-1 with resistance-associated mutations to this drug 2009 ·Journal of Antimicrobial Chemotherapy ·Marc Wirden, A. Simon, Lars Schneider, Roland Tubiana, (unknown), Hocine Aït-Mohand, (unknown), Christine Katlama, Vincent Cálvez, Anne‐Geneviève Marcelin	20
14	Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients 2009 ·Journal of Antimicrobial Chemotherapy ·Isabelle Malet, Olivier Delelis, Cathia Soulié, Marc Wirden, Luba Tchertanov, (unknown), Gilles Peytavin, Christine Katlama, Jean‐François Mouscadet, Vincent Cálvez, Anne‐Geneviève Marcelin	76
15	Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996–2006 in France 2009 ·AIDS ·Marie‐Laure Chaix, Diane Descamps, Marc Wirden, Laurence Bocket, Constance Delaugerre, Catherine Tamalet, Véronique Schneider, Jacques Izopet, Bernard Masquelier, Christine Rouzioux, Laurence Meyer, Dominique Costagliola	64
16	Antiretroviral combinations implicated in emergence of the L74I and L74V resistance mutations in HIV-1-infected patients 2008 ·AIDS ·Marc Wirden, Sidonie Lambert-Niclot, Anne‐Geneviève Marcelin, Luminita Schneider, Hocine Aït-Mohand, (unknown), (unknown), (unknown), Christine Katlama, Vincent Cálvez	13
17	HIV-related nephropathies associated with changes in blood and kidney tissue virus load 2008 ·Kidney International ·Vincent Audard, Jérôme Avouac, Marc Wirden, Agathe Pardon, Marie Matignon, Philippe Rémy, Dominique Desvaux, Philippe Lang, (unknown)	0
18	Association of Gag cleavage sites to protease mutations and to virological response in HIV-1 treated patients 2006 ·Journal of Infection ·Isabelle Malet, Bénédicte Roquebert, Cécile Dalban, Marc Wirden, Bahia Amellal, Rachid Agher, Anne Simon, Christine Katlama, Dominique Costagliola, Vincent Cálvez, Anne‐Geneviève Marcelin	44
19	Resistance mutations before and after tenofovir regimen failure in HIV-1 infected patients 2005 ·Journal of Medical Virology ·Marc Wirden, Anne‐Geneviève Marcelin, Anne Simon, Myriam Kirstetter, Roland Tubiana, Marc‐Antoine Valantin, Luc Paris, Manuela Bonmarchand, (unknown), (unknown), Christine Katlama, Vincent Cálvez	16
20	MIV-310 reduces HIV viral load in patients failing multiple antiretroviral therapy 2004 ·AIDS ·Christine Katlama, Jade Ghosn, Roland Tubiana, Marc Wirden, Marc‐Antoine Valantin, Johan Harmenberg, (unknown), Bo Öberg, Vincent Cálvez	15

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact